menu
    • menu
    [{"orgOrder":0,"company":"Tesaro","sponsor":"AnaptysBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tesaro \/ Tesaro","highestDevelopmentStatusID":"15","companyTruncated":"Tesaro \/ Tesaro"},{"orgOrder":0,"company":"Tesaro","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase II","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tesaro \/ Tesaro","highestDevelopmentStatusID":"8","companyTruncated":"Tesaro \/ Tesaro"},{"orgOrder":0,"company":"Tesaro","sponsor":"Tesaro","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tesaro \/ Tesaro","highestDevelopmentStatusID":"6","companyTruncated":"Tesaro \/ Tesaro"},{"orgOrder":0,"company":"Tesaro","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tesaro \/ Tesaro","highestDevelopmentStatusID":"8","companyTruncated":"Tesaro \/ Tesaro"},{"orgOrder":0,"company":"Tesaro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tesaro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tesaro \/ Inapplicable"},{"orgOrder":0,"company":"Tesaro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tesaro \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Tesaro

    Menu

    Tesaro

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niraparib Tosylate,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participan...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 09, 2025

                            Lead Product(s) : Niraparib Tosylate,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dostarlimab,Bevacizumab,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurren...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 02, 2023

                            Lead Product(s) : Dostarlimab,Bevacizumab,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dostarlimab,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : AnaptysBio

                            Deal Size : $240.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            FDA Grants Accelerated Approval of Jemperli (Dostarlimab-gxly) for DMMR Recurrent or Advanced Solid Tumors

                            Details : JEMPERLI was generated by AnaptysBio using its proprietary somatic hypermutation (SHM) antibody platform and subsequently developed by TESARO, Inc., now a part of GSK, under a collaboration agreement.

                            Product Name : Jemperli

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            August 17, 2021

                            Lead Product(s) : Dostarlimab,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : AnaptysBio

                            Deal Size : $240.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dostarlimab,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Memorial Sloan Kettering Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 01, 2021

                            Lead Product(s) : Dostarlimab,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Memorial Sloan Kettering Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niraparib Tosylate,Doxorubicin Hydrochloride,Cyclophosphamide,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Wake Forest University Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 21, 2021

                            Lead Product(s) : Niraparib Tosylate,Doxorubicin Hydrochloride,Cyclophosphamide,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Wake Forest University Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niraparib Tosylate,Dostarlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Niraparib + Dostarlimab + RT in Pancreatic Cancer

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 01, 2020

                            Lead Product(s) : Niraparib Tosylate,Dostarlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            08

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dostarlimab,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Diwakar Davar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) Vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 25, 2019

                            Lead Product(s) : Dostarlimab,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Diwakar Davar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niraparib Tosylate,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Northwell Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 06, 2019

                            Lead Product(s) : Niraparib Tosylate,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Northwell Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niraparib Tosylate,Dostarlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : University of Oklahoma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 28, 2019

                            Lead Product(s) : Niraparib Tosylate,Dostarlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : University of Oklahoma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth